CURE Media Group was honored with 4 Digital Health Awards from a competition that recognizes the world’s best digital health resources.
CURE® Media Group, the nation’s leading digital and print media enterprise dedicated to patients and survivors of cancer, as well as the nurses who care for them, was honored with 4 Digital Health Awards®, a competition that recognizes the world’s best digital health resources. Winning contributions for the Spring 2018 session included:
“We are honored to receive four Digital Health Awards® from the Health Information Resource Center, said, Michael J. Hennessy Jr, president of MJH Associates, parent company of CURE® Media Group. “These awards show the dedication and passion our editorial teams put forth each day.”
The competition—held each spring and fall—featured 80 categories. CURE® magazine and Oncology Nursing News® were selected from more than 400 entries.
The Health Information Resource CenterSM (HIRC), organizer of the Digital Health Awards, is a national information clearinghouse for professionals who work in consumer health fields.
About CURE Media Group
CURE Media Group is the leading resource for cancer updates, research and education. It combines a full suite of media products, including its industry-leading website, curetoday.com; innovative video programs, such as CURE Connections®; a series of widely attended live events; and CURE® magazine, which reaches over 1 million readers, as well as the website for oncology nurses, OncNursingNews.com®, and its companion, Oncology Nursing News® magazine. CURE Media Group is part of the Cranbury, New Jersey—based MJH Associates Inc. family of businesses, which includes the acclaimed OncLive® (onclive.com) platform of resources for the practicing oncologist. For more information, visit curetoday.com or mjhassoc.com.
Early Data May Show PFS Benefit With Cancer Vaccine in Metastatic CRC
April 13th 2024Patients with metastatic microsatellite stable colorectal cancer treated with a personalized neoantigen cancer vaccine after chemotherapy demonstrated an early trend towards a progression-free survival benefit.